CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Early-Stage Biotech's AI Advantage Is A Window That Closes

  FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

• Where PRO Strategy Goes Wrong

  PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

• Is The Industry Ready To Trust LLMs With Chart Review?

  See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

• Artificial Intelligence, Virtual Participants, and the Evolving FDA Regulatory Landscape

  Understanding emerging requirements around transparency, risk, and governance is essential for responsibly advancing AI-driven innovation in regulated environments.

• The Regulatory Governance Gap In Clinical Trial AI

  Regulators are no longer questioning whether AI belongs in clinical trials; however, they’re demanding a governed infrastructure that makes every AI-driven decision auditable and defensible.